title: ATP precursor depletion and postischemic myocardial recovery.
abstract: Although cardioplegia reduces myocardial metabolism during ischemia, adenosine triphosphate (ATP) depletion occurs, which may contribute to poor functional recovery after reperfusion. Augmenting myocardial adenosine during ischemia is successful in improving ATP repletion and myocardial recovery following ischemia. If adenosine is an important determinant of ischemic tolerance, then depletion or elimination of myocardial adenosine should lead to poor functional and metabolic recovery after ischemia. To test this hypothesis, isolated, perfused rabbit hearts were subjected to 120 min of 34 degrees C ischemia. Hearts received St. Thomas cardioplegia alone or cardioplegia containing 200 microM adenosine, or cardioplegia containing 15, 5, 2.5, or 0.025 micrograms/ml adenosine deaminase (ADA), which catalyzes the breakdown of adenosine to inosine, making adenosine unavailable as an ATP precursor. Functional recovery was determined and myocardial nucleotide levels were measured before, during, and after ischemia. Following ischemia and reperfusion, control hearts recovered to 51 +/- 3% of preischemic developed pressure (DP). There was significantly better recovery in adenosine-augmented hearts (68 +/- 7%), while ADA hearts had significantly worse recovery. Hearts treated with 0.025 microgram/ml ADA recovered to only 29 +/- 5% of DP and higher dose ADA hearts failed to demonstrate any recovery of systolic function. Furthermore, adenosine enhanced metabolic recovery, whereas ADA resulted in greatly depleted ATP and precursor reserves. Postischemic developed pressure closely paralleled the availability of myocardial adenosine, consistent with the hypothesis that myocardial adenosine levels at end ischemia and early reperfusion are important determinants of functional recovery after global ischemia.
authors.affiliation: Department of Surgery (Section of Thoracic Surgery), University of Michigan Medical School, Ann Arbor 48109.
authors.forename: S F
authors.initials: SF
authors.lastname: Bolling
authors.forename: E L
authors.initials: EL
authors.lastname: Bove
authors.forename: K P
authors.initials: KP
authors.lastname: Gallagher
mesh_terms: D000241:Adenosine / Q000172:deficiency* / Q000494:pharmacology; D000243:Adenosine Deaminase / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000096:biosynthesis*; D000818:Animals; D003327:Coronary Disease / Q000378:metabolism* / Q000503:physiopathology; D006321:Heart / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D015425:Myocardial Reperfusion; D009206:Myocardium / Q000378:metabolism*; D009711:Nucleotides / Q000378:metabolism; D011817:Rabbits; D016277:Ventricular Function, Left
chemical_list: D009711:Nucleotides; D000255:Adenosine Triphosphate; D000243:Adenosine Deaminase; D000241:Adenosine